Our results indicated that Bru is a novel Akt1 inhibitor with significantly anti-ESCC potential by directly binding to Akt to inhibit the Akt1 pathway through the reduction of its phosphorylation. Here, AKT1 is linked to esophageal squamous cell carcinoma.